Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN N versus PENICILLIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN N versus PENICILLIN 2.
OMNIPEN-N vs PENICILLIN-2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
None Documented
None Documented
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic